The Biomedical Advanced Research and Development Authority is funding trials for “next-generation” nasal and oral COVID-19 vaccines. Scientists who spoke with The Defender cautioned about potential vaccine shedding and long-term efficacy while criticizing the use of existing mRNA vaccines as comparators in the studies.

The funding, awarded through the Biomedical Advanced Research and Development Authority (BARDA) under HHS’ Administration for Strategic Preparedness and Response (ASPR), will support Phase 2b clinical trials for Vaxart‘s oral pill vaccine (up to $453 million) and CyanVac’s (up to $40 million) and Castlevax’s ($34 million) intranasal vaccines.

Each company’s phase 2b trials will recruit 10,000 volunteers to compare the safety and efficacy of the investigational vaccine against the existing mRNA vaccines.

https://childrenshealthdefense.org/defender/hhs-covid-nasal-vaccine-trial/?

 

How about paying for a study to compare these “new” methodologies with drugs KNOW to cure COVID without the need for vaccines. This is just another boondoggle on the taxpayer purse for the benefit of pharma industry. Let them pay for their own research and get the drugs that work into the marketplace!